Last updated: February 23, 2026
What is the drug associated with NDC 42806-0656?
NDC 42806-0656 identifies a formulation of Ibutamoren (MK-677), an oral growth hormone secretagogue in development. It is used to stimulate growth hormone and IGF-1 release, primarily investigated for conditions like cachexia, growth hormone deficiency, and muscle wasting.
Market landscape overview
Market status
- Development stage: Experimental/clinical-stage. No FDA approval or widespread commercial availability.
- Research focus: Primary interest in clinical trials targeting cachexia, osteoporosis, and sarcopenia.
- Key players: Numerous biopharmas and biotech startups; no dominant market leader yet.
Potential market drivers
- An aging population worldwide increases demand for treatments addressing muscle wasting and frailty.
- Growing interest in muscle health and anti-aging therapies.
- Clinical trial outcomes show promising efficacy in increasing muscle mass and improving physical function.
Competitive environment
| Company |
Compound |
Phase |
Indications |
Market share |
Notes |
| Pfizer |
Experimental |
Phase 2 |
Cachexia, muscle wasting |
N/A |
Leading innovation, no approved drug yet |
| RedHill Bio |
RHB-104 |
Phase 2 |
Sarcopenia, growth hormone deficiency |
N/A |
Focus on autoimmune and infectious diseases |
| Several startups |
Various |
Preclinical |
Muscle atrophy, osteoporosis |
N/A |
Competitive preclinical pipeline |
Pricing and reimbursement
- No commercial sales; prices are speculative, based on similar compounds.
- Clinical trial costs for drugs in this class range from $10 million to $50 million.
- Future pricing likely driven by efficacy, safety profile, and reimbursement negotiations.
Price projections (speculative, based on analogous drugs)
| Year |
Estimated price per treatment course |
Assumptions |
| 2023 |
$50,000 |
Clinical-stage, limited data, high development risk |
| 2024 |
$45,000 |
Positive Phase 2 results, increased investor confidence |
| 2025 |
$40,000 |
Progress toward approval, rising competition |
| 2026 |
$35,000 |
Near-term approval possibility, cost reductions expected |
Cost factors influencing pricing
- Complexity of manufacturing oral peptides.
- Efficacy and safety data from ongoing trials.
- Patent protection and exclusivity; likely 10-12 years from approval.
- Reimbursement policies favor high-value therapies for muscle-wasting conditions.
Regulatory outlook
- Current status: No FDA approval; in early-stage trials.
- Expected timeline: Phase 3 trials anticipated within 2-3 years, with potential approval 4-5 years post-first human studies.
- Challenges: Safety concerns regarding long-term growth hormone modulation.
Conclusion: Market prospects and strategic considerations
- Early-stage, with significant unmet needs in cachexia and age-related muscle loss.
- Commercial success depends on positive clinical outcomes, safety, and regulatory approval.
- Pricing likely to align with other growth hormone and peptide therapies, within $30,000–$50,000 per treatment course.
- Competitive landscape remains nascent; early entrants could establish market dominance.
Key takeaways
- NDC 42806-0656 corresponds to Ibutamoren, a growth hormone secretagogue still in clinical development.
- The market is driven by aging populations and conditions involving muscle wasting. No current approvals make this a high-risk, high-reward investment.
- Price projections range from $35,000 to $50,000 per treatment course within five years based on analogs and development progress.
- Market success relies on positive trial data, regulatory approval, and reimbursement frameworks.
FAQs
Q1: When might Ibutamoren (NDC 42806-0656) reach the market?
Expect potential regulatory approval in 4-5 years if ongoing trials demonstrate safety and efficacy.
Q2: How does the pricing of Ibutamoren compare to related therapies?
Similar therapies, such as growth hormone formulations, cost between $20,000 and $50,000 annually, suggesting comparable market pricing for Ibutamoren.
Q3: What are the main challenges in commercializing this drug?
Key issues include demonstrating safety for long-term use, obtaining regulatory approval, and establishing reimbursement pathways.
Q4: What therapeutic areas will benefit most from this drug?
Muscle-wasting conditions, cachexia associated with chronic illness, and age-related sarcopenia.
Q5: Which competitors are emerging in this space?
No direct commercial competitors exist yet. Several biotech firms are in early research stages exploring similar mechanisms.
References
- U.S. Food and Drug Administration. (2022). Types of drugs in development. FDA.gov.
- MarketsandMarkets. (2023). Growth hormone therapeutic market analysis.
- ClinicalTrials.gov. (2023). Ibutamoren (MK-677) trials.
- Pharmaceutical Data Analytics. (2022). Pricing models for peptide therapies.
- BIO Industry Reports. (2023). Early-stage biotech competitive landscape.
